The Interrelationship between HIV Infection and COVID-19: A Review of the Literature


Cite item

Full Text

Abstract

The Corona Virus Disease 2019 (COVID-19) pandemic resulting from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to significant morbidity and mortality in patients and put a strain on healthcare systems worldwide. The clinical characteristics and results of COVID-19 in immunosuppressed patients, such as people living with human immunodeficiency virus (PLWH), considered at higher risk of severe disease, are not well-characterized. Accumulated evidence indicates that COVID-19 and the human immunodeficiency virus (HIV) can interact in various ways. This review explored the similarities and differences in virology between SARS-CoV-2 and HIV, the effect of the COVID-19 vaccine on PLWH, the impact of the COVID-19 pandemic on PLWH care and prevention, and the influence of HIV-related factors on COVID-19. Discovering the potential link between HIV and COVID-19 may provide a novel way to avoid the factors of HIV and SARS-CoV-2 coinfection and advance future research.

About the authors

Yiyu Wang

School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine

Email: info@benthamscience.net

Yu Lai

School of Basic Medicine, Chengdu University of Traditional Chinese Medicine

Author for correspondence.
Email: info@benthamscience.net

References

  1. Organization WH. HO Director-General’s opening remarks at the media briefing on COVID-19-11 March. Geneva, Switzerland 2020.
  2. Coronavirus disease (COVID-19) data. 2023.
  3. Data on the size of the HIV epidemic. 2021.
  4. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008; 372(9635): 293-9. doi: 10.1016/S0140-6736(08)61113-7 PMID: 18657708
  5. Li M, Wang H, Tian L, et al. COVID-19 vaccine development: Milestones, lessons and prospects. Signal Transduct Target Ther 2022; 7(1): 146. doi: 10.1038/s41392-022-00996-y PMID: 35504917
  6. Menza TW, Capizzi J, Zlot AI, Barber M, Bush L. COVID-19 vaccine uptake among people living with HIV. AIDS Behav 2022; 26(7): 2224-8. doi: 10.1007/s10461-021-03570-9 PMID: 34994913
  7. Chun HM, Milligan K, Agyemang E, et al. A systematic review of COVID-19 vaccine antibody responses in people with HIV. Open Forum Infect Dis 2022; 9(11): ofac579. doi: 10.1093/ofid/ofac579 PMID: 36438620
  8. D’Souza G, Springer G, Gustafson D, et al. COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: The MACS/WIHS combined cohort study. HIV Res Clin Pract 2020; 21(5): 130-9. doi: 10.1080/25787489.2020.1844521 PMID: 33211636
  9. Spinelli MA, Jones BLH, Gandhi M. COVID-19 outcomes and risk factors among people living with HIV. Curr HIV/AIDS Rep 2022; 19(5): 425-32. doi: 10.1007/s11904-022-00618-w PMID: 35930187
  10. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: A systematic review. HIV Med 2020; 21(9): 567-77. doi: 10.1111/hiv.12911 PMID: 32671970
  11. Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 among people living with HIV: A systematic review. AIDS Behav 2021; 25(1): 85-92. doi: 10.1007/s10461-020-02983-2 PMID: 32734438
  12. Prabhu S, Poongulali S, Kumarasamy N. Impact of COVID-19 on people living with HIV: A review. J Virus Erad 2020; 6(4): 100019. doi: 10.1016/j.jve.2020.100019 PMID: 33083001
  13. Duerr R, Crosse KM, Valero-Jimenez AM, Dittmann M. SARS-CoV-2 portrayed against HIV: Contrary viral strategies in similar disguise. Microorganisms 2021; 9(7): 1389. doi: 10.3390/microorganisms9071389 PMID: 34198973
  14. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study. Chin Med J 2020; 133(9): 1015-24. doi: 10.1097/CM9.0000000000000722 PMID: 32004165
  15. Baltimore D. Expression of animal virus genomes. Bacteriol Rev 1971; 35(3): 235-41. doi: 10.1128/br.35.3.235-241.1971 PMID: 4329869
  16. Mahmoudabadi G, Phillips R. A comprehensive and quantitative exploration of thousands of viral genomes. eLife 2018; 7: e31955. doi: 10.7554/eLife.31955 PMID: 29624169
  17. Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of infection: A brief overview. Ann Ist Super Sanita 2010; 46(1): 5-14. doi: 10.1590/S0021-25712010000100002 PMID: 20348614
  18. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9. doi: 10.1038/s41586-020-2008-3 PMID: 32015508
  19. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med 2012; 2(11): a006965. doi: 10.1101/cshperspect.a006965 PMID: 23043157
  20. General Office of National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for Novel Coronavirus Pneumonia. 2020; pp. 1-13.
  21. Rein A. RNA packaging in HIV. Trends Microbiol 2019; 27(8): 715-23. doi: 10.1016/j.tim.2019.04.003 PMID: 31085095
  22. Savastano A, Ibáñez de Opakua A, Rankovic M, Zweckstetter M. Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. Nat Commun 2020; 11(1): 6041. doi: 10.1038/s41467-020-19843-1 PMID: 33247108
  23. Mattei S, Glass B, Hagen WJH, Kräusslich HG, Briggs JAG. The structure and flexibility of conical HIV-1 capsids determined within intact virions. Science 2016; 354(6318): 1434-7. doi: 10.1126/science.aah4972 PMID: 27980210
  24. Campbell EM, Hope TJ. HIV-1 capsid: The multifaceted key player in HIV-1 infection. Nat Rev Microbiol 2015; 13(8): 471-83. doi: 10.1038/nrmicro3503 PMID: 26179359
  25. Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Sci 2021; 41(6): 1037-51. doi: 10.1007/s11596-021-2395-1 PMID: 34241776
  26. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020; 181(5): 1016-1035.e19. doi: 10.1016/j.cell.2020.04.035 PMID: 32413319
  27. Illanes-Álvarez F, Márquez-Ruiz D, Márquez-Coello M, Cuesta-Sancho S, Girón-González JA. Similarities and differences between HIV and SARS-CoV-2. Int J Med Sci 2021; 18(3): 846-51. doi: 10.7150/ijms.50133 PMID: 33437221
  28. Watts JM, Dang KK, Gorelick RJ, et al. Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 2009; 460(7256): 711-6. doi: 10.1038/nature08237 PMID: 19661910
  29. Fung M, Babik JM. COVID-19 in immunocompromised hosts: What we know so far. Clin Infect Dis 2021; 72(2): 340-50. doi: 10.1093/cid/ciaa863 PMID: 33501974
  30. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020; 92(4): 441-7. doi: 10.1002/jmv.25689 PMID: 31994742
  31. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5 PMID: 31986264
  32. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med 2020; 201(4): 7-P8. doi: 10.1164/rccm.2014P7 PMID: 32004066
  33. Bangham CRM, McMichael AJ. Why the long latent period? Nature 1990; 348(6300): 388. doi: 10.1038/348388a0 PMID: 1978928
  34. Vaillant AJ, Gulick P. HIV disease StatPearls. StatPearls Publishing 2019.
  35. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382(13): 1199-207. doi: 10.1056/NEJMoa2001316 PMID: 31995857
  36. Li L, Huang T, Wang Y, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020; 92(6): 577-83. doi: 10.1002/jmv.25757 PMID: 32162702
  37. Liu Y, Han J, Li X, et al. COVID-19 vaccination in people living with HIV (PLWH) in China: A cross sectional study of vaccine hesitancy, safety, and immunogenicity. Vaccines 2021; 9(12): 1458. doi: 10.3390/vaccines9121458 PMID: 34960204
  38. Duly K, Farraye FA, Bhat S. COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations. Am J Health Syst Pharm 2022; 79(2): 63-71. doi: 10.1093/ajhp/zxab344 PMID: 34455440
  39. Vasan S, Pitisuttithum P. Vaccine development lessons between HIV and COVID-19. Lancet Infect Dis 2021; 21(6): 759-61. doi: 10.1016/S1473-3099(21)00274-7 PMID: 34051181
  40. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20. doi: 10.1056/NEJMoa0908492 PMID: 19843557
  41. Han X, Yu X, Han Y, et al. Safety and immunogenicity of inactivated COVID-19 vaccines among people living with HIV in China. Infect Drug Resist 2022; 15: 2091-100. doi: 10.2147/IDR.S353127 PMID: 35480056
  42. Kang L, Shang W, Gao P, Wang Y, Liu J, Liu M. Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis. Vaccines 2022; 10(9): 1569. doi: 10.3390/vaccines10091569 PMID: 36146647
  43. Vallée A, Fourn E, Majerholc C, Touche P, Zucman D. COVID-19 vaccine hesitancy among french people living with HIV. Vaccines 2021; 9(4): 302. doi: 10.3390/vaccines9040302 PMID: 33804808
  44. Bogart LM, Ojikutu BO, Tyagi K, et al. COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among black americans living with HIV. J Acquir Immune Defic Syndr 2021; 86(2): 200-7. doi: 10.1097/QAI.0000000000002570 PMID: 33196555
  45. Yao Y, Chai R, Yang J, et al. Reasons for COVID-19 vaccine hesitancy among chinese people living with HIV/AIDS: Structural equation modeling analysis. JMIR Public Health Surveill 2022; 8(6): e33995. doi: 10.2196/33995 PMID: 35486810
  46. Kaida A, Brotto LA, Murray MCM, et al. Intention to receive a COVID-19 vaccine by HIV status among a population-based sample of women and gender diverse individuals in British Columbia, Canada. AIDS Behav 2022; 26(7): 2242-55. doi: 10.1007/s10461-022-03577-w PMID: 35020094
  47. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021; 384(23): 2187-201. doi: 10.1056/NEJMoa2101544 PMID: 33882225
  48. Logunov DY, Livermore DM, Ornelles DA, et al. COVID-19 vaccination and HIV-1 acquisition. Lancet 2022; 399(10333): e34-5. doi: 10.1016/S0140-6736(22)00332-4 PMID: 35397866
  49. Ten threats to global health in 2019 2019.
  50. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2020; 323(13): 1239-42. doi: 10.1001/jama.2020.2648 PMID: 32091533
  51. COVID-19 vaccines and HIV 2021.
  52. Frescura L, Godfrey-Faussett P, Feizzadeh A A, El-Sadr W, Syarif O, Ghys PD. Achieving the 95 95 95 targets for all: A pathway to ending AIDS. PLoS One 2022; 17(8): e0272405. doi: 10.1371/journal.pone.0272405 PMID: 35925943
  53. Guaraldi G, Milic J, Martinez E, et al. Human immunodeficiency virus (HIV) care models during the coronavirus disease 2019 (COVID-19) era. Clin Infect Dis 2021; 73(5): e1222-7. doi: 10.1093/cid/ciaa1864 PMID: 34492689
  54. Roy K, Himelfarb A, Karrah K, et al. The social, behavioral, and ethical modalities of COVID-19 on HIV care in South Africa: A systematic review. Int J Environ Res Public Health 2022; 19(15): 9766. doi: 10.3390/ijerph19159766 PMID: 35955119
  55. Kowalska JD, Skrzat-Klapaczyńska A, Bursa D, et al. HIV care in times of the COVID-19 crisis - Where are we now in Central and Eastern Europe? Int J Infect Dis 2020; 96: 311-4. doi: 10.1016/j.ijid.2020.05.013 PMID: 32413608
  56. Qiao S, Yang X, Sun S, et al. Challenges to HIV service delivery and the impacts on patient care during COVID-19: perspective of HIV care providers in Guangxi, China. AIDS Care 2021; 33(5): 559-65. doi: 10.1080/09540121.2020.1849532 PMID: 33242981
  57. Disruption in HIV, Hepatitis and STI services due to COVID-19 2020.
  58. Sun S, Hou J, Chen Y, Lu Y, Brown L, Operario D. Challenges to HIV care and psychological health during the COVID-19 pandemic among people living with HIV in China. AIDS Behav 2020; 24(10): 2764-5. doi: 10.1007/s10461-020-02903-4 PMID: 32382824
  59. Pinto RM, Park S. COVID-19 pandemic disrupts HIV continuum of care and prevention: Implications for research and practice concerning community-based organizations and frontline providers. AIDS Behav 2020; 24(9): 2486-9. doi: 10.1007/s10461-020-02893-3 PMID: 32347403
  60. Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: A syndemic perspective. AIDS Behav 2020; 24(8): 2244-9. doi: 10.1007/s10461-020-02871-9 PMID: 32303925
  61. Krakower D, Solleveld P, Levine K, Mayer K. Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center. J Int AIDS Soc 2020; 176-7.
  62. Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in sub-Saharan Africa during COVID-19. J Int AIDS Soc 2021; 24(6): e25704. doi: 10.1002/jia2.25704 PMID: 34105884
  63. Jewell BL, Mudimu E, Stover J, et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: Results from multiple mathematical models. Lancet HIV 2020; 7(9): e629-40. doi: 10.1016/S2352-3018(20)30211-3 PMID: 32771089
  64. Holmes EA, O’Connor RC, Perry VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: A call for action for mental health science. Lancet Psychiatry 2020; 7(6): 547-60. doi: 10.1016/S2215-0366(20)30168-1 PMID: 32304649
  65. Shin S, Muñoz M, Espiritu B, et al. Psychosocial impact of poverty on antiretroviral nonadherence among HIV-TB coinfected patients in Lima, Peru. J Int Assoc Physicians AIDS Care (Chic) 2008; 7(2): 74-81. doi: 10.1177/1545109708315326 PMID: 18319510
  66. Wu DY, Munoz M, Espiritu B, et al. Burden of depression among impoverished HIV-positive women in Peru. J Acquir Immune Defic Syndr 2008; 48(4): 500-4. doi: 10.1097/QAI.0b013e31817dc3e9 PMID: 18614919
  67. Zafra-Tanaka JH, Ticona-Chavez E. Stigma related to HIV/AIDS associated with adherence to antiretroviral therapy in patients of a public hospital in Lima, Peru 2014. Rev Peru Med Exp Salud Publica 2016; 33(4): 625-32. doi: 10.17843/rpmesp.2016.334.2544 PMID: 28327830
  68. Earnshaw VA, Bogart LM, Laurenceau JP, et al. Internalized HIV stigma, ART initiation and HIV -1 RNA suppression in South Africa: Exploring avoidant coping as a longitudinal mediator. J Int AIDS Soc 2018; 21(10): e25198. doi: 10.1002/jia2.25198 PMID: 30362662
  69. Budak JZ, Scott JD, Dhanireddy S, Wood BR. The impact of COVID-19 on HIV care provided via telemedicine-past, present, and future. Curr HIV/AIDS Rep 2021; 18(2): 98-104. doi: 10.1007/s11904-021-00543-4 PMID: 33616811
  70. Bell N, Bracchi M, Dalla Pria A, Nelson M, Boffito M. Indirect human immunodeficiency virus morbidity and mortality due to coronavirus disease 2019. Clin Infect Dis 2021; 73(10): 1947-9. doi: 10.1093/cid/ciab128 PMID: 33580253
  71. Mehta SA, Rana MM, Motter JD, et al. Incidence and outcomes of COVID-19 in kidney and liver transplant recipients with HIV: Report from the national hope in action consortium. Transplantation 2021; 105(1): 216-24. doi: 10.1097/TP.0000000000003527 PMID: 33165238
  72. Nagarakanti SR, Okoh AK, Grinberg S, Bishburg E. Clinical outcomes of patients with COVID-19 and HIV co-infection. J Med Virol 2021; 93(3): 1687-93. doi: 10.1002/jmv.26533 PMID: 32949148
  73. Waters LJ, Pozniak AL. COVID-19 death in people with HIV: Interpret cautiously. Lancet HIV 2021; 8(1): e2-3. doi: 10.1016/S2352-3018(20)30332-5 PMID: 33316210
  74. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 2021; 8(1): e24-32. doi: 10.1016/S2352-3018(20)30305-2 PMID: 33316211
  75. Looha MA, Taraghikhah N, Amini M, et al. The impact of HIV on the risk of COVID-19 death among hospitalized patients. Hum Antibodies 2023; 30(4): 165-75. doi: 10.3233/HAB-220011 PMID: 36617778
  76. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One 2020; 15(8): e0238215. doi: 10.1371/journal.pone.0238215 PMID: 32845926
  77. Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses. J Med Virol 2021; 93(4): 2385-95. doi: 10.1002/jmv.26740 PMID: 33331656
  78. Venturas J, Zamparini J, Shaddock E, et al. Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19. J Infect 2021; 83(2): 217-27. doi: 10.1016/j.jinf.2021.05.020 PMID: 34051225
  79. Diagnoses of HIV Infection in the United States and Dependent Areas 2016 2017.
  80. Islam JY, Madhira V, Sun J, et al. Racial disparities in COVID-19 test positivity among people living with HIV in the United States. Int J STD AIDS 2022; 33(5) doi: 10.1177/09564624221074468 PMID: 35306931
  81. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One 2011; 6(8): e17502. doi: 10.1371/journal.pone.0017502 PMID: 21826193
  82. Varshney K, Ghosh P, Stiles H, Iriowen R. Risk factors for COVID-19 mortality among people living with HIV: A scoping review. AIDS Behav 2022; 26(7): 2256-65. doi: 10.1007/s10461-022-03578-9 PMID: 35024992
  83. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584(7821): 430-6. doi: 10.1038/s41586-020-2521-4 PMID: 32640463
  84. Etienne N, Karmochkine M, Slama L, et al. HIV infection and COVID-19: Risk factors for severe disease. AIDS 2020; 34(12): 1771-4. doi: 10.1097/QAD.0000000000002651 PMID: 32773476
  85. Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine 2020; 23: 100404. doi: 10.1016/j.eclinm.2020.100404 PMID: 32632416
  86. Crepaz N, Dong X, Wang X, Hernandez AL, Hall HI. Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons receiving HIV care - United States, 2014. MMWR Morb Mortal Wkly Rep 2018; 67(4): 113-8. doi: 10.15585/mmwr.mm6704a2 PMID: 29389918
  87. Simard EP, Fransua M, Naishadham D, Jemal A. The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med 2012; 172(20): 1591-8. doi: 10.1001/archinternmed.2012.4508 PMID: 23045164
  88. Simoni JM, Huh D, Wilson IB, et al. Racial/Ethnic disparities in ART adherence in the United States: Findings from the MACH14 study. J Acquir Immune Defic Syndr 2012; 60(5): 466-72. doi: 10.1097/QAI.0b013e31825db0bd PMID: 22595873
  89. Millett GA. New pathogen, same disparities: Why COVID‐19 and HIV remain prevalent in U.S. Communities of colour and implications for ending the HIV epidemic. J Int AIDS Soc 2020; 23(11): e25639. doi: 10.1002/jia2.25639 PMID: 33222424
  90. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20. doi: 10.1056/NEJMoa2002032 PMID: 32109013
  91. Jiang M, Guo Y, Luo Q, et al. T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J Infect Dis 2020; 222(2): 198-202. doi: 10.1093/infdis/jiaa252 PMID: 32379887
  92. Zhang H, Wu T. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis. J Infect 2020; 81(3): e82-4. doi: 10.1016/j.jinf.2020.06.036 PMID: 32569604
  93. Ho H, Peluso MJ, Margus C, et al. Clinical outcomes and immunologic characteristics of coronavirus disease 2019 in people with human immunodeficiency virus. J Infect Dis 2021; 223(3): 403-8. doi: 10.1093/infdis/jiaa380 PMID: 32601704
  94. Tesoriero JM, Swain CAE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open 2021; 4(2): e2037069. doi: 10.1001/jamanetworkopen.2020.37069 PMID: 33533933
  95. Davies M-A. HIV and risk of COVID-19 death: A population cohort study from the western cape province, South Africa. MedRxiv 2020; 2020.07. doi: 10.1101/2020.07.02.20145185
  96. del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: A cohort study. Ann Intern Med 2020; 173(7): 536-41. doi: 10.7326/M20-3689 PMID: 32589451
  97. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol 2020; 20(6): 363-74. doi: 10.1038/s41577-020-0311-8 PMID: 32346093
  98. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020; 382(19): 1787-99. doi: 10.1056/NEJMoa2001282 PMID: 32187464
  99. Bertagnolio S, Thwin SS, Silva R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: Analysis of data from the WHO global clinical platform of COVID-19. Lancet HIV 2022; 9(7): e486-95. doi: 10.1016/S2352-3018(22)00097-2 PMID: 35561704
  100. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 2015; 116: 76-84. doi: 10.1016/j.antiviral.2015.01.011 PMID: 25666761
  101. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149-50. doi: 10.1038/d41573-020-00016-0 PMID: 32127666
  102. Chan JFW, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212(12): 1904-13. doi: 10.1093/infdis/jiv392 PMID: 26198719
  103. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; 323(15): 1488-94. doi: 10.1001/jama.2020.3204 PMID: 32125362
  104. Han W, Quan B, Guo Y, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol 2020; 92(5): 461-3. doi: 10.1002/jmv.25711 PMID: 32073161
  105. Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020; 95: 183-91. doi: 10.1016/j.ijid.2020.03.013 PMID: 32173576
  106. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13. doi: 10.1016/S0140-6736(20)30211-7 PMID: 32007143
  107. Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253: 117592. doi: 10.1016/j.lfs.2020.117592 PMID: 32222463
  108. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323(20): 2052-9. doi: 10.1001/jama.2020.6775 PMID: 32320003
  109. Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort. Lancet HIV 2020; 7(8): e554-64. doi: 10.1016/S2352-3018(20)30164-8 PMID: 32473657
  110. Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: Summary of the data and responses to date. Curr Opin HIV AIDS 2021; 16(1): 63-73. doi: 10.1097/COH.0000000000000659 PMID: 33186229
  111. Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: A single-arm substudy of a phase 2/3 clinical trial. Lancet HIV 2021; 8(8): e474-85. doi: 10.1016/S2352-3018(21)00103-X PMID: 34153264
  112. Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslén M, Björkman P. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One 2017; 12(7): e0180761. doi: 10.1371/journal.pone.0180761 PMID: 28683128
  113. Gray ES, Madiga MC, Hermanus T, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85(10): 4828-40. doi: 10.1128/JVI.00198-11 PMID: 21389135
  114. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 45(5): 483-93. doi: 10.1097/QAI.0b013e3180654836 PMID: 17496565
  115. Stover J, Kelly SL, Mudimu E, et al. The risks and benefits of providing HIV services during the COVID-19 pandemic. PLoS One 2021; 16(12): e0260820. doi: 10.1371/journal.pone.0260820 PMID: 34941876
  116. Ayerdi O, Puerta T, Clavo P, et al. Preventive efficacy of tenofovir/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users. Open Forum Infect Dis 2020; 7(11): ofaa455. doi: 10.1093/ofid/ofaa455 PMID: 33200081
  117. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76(16): 1815-26. doi: 10.1016/j.jacc.2020.08.041 PMID: 32860872

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers